Hims & Hers Health (HIMS) has disclosed plans to shut down Apostrophe, its acne treatment business. This change is part of ...

Hims & Hers Health, Inc. stock faces volatility after an FDA halt on its GLP-1 drug. Click here to find out why HIMS stock is ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Hims & Hers Health ... CA-based health and wellness platform have gained 8.6% in the past three months, outperforming the industry’s 0.4% loss. In the same time frame, the stock outperformed ...

Hims and Hers plans to stop selling compounded weight loss ... "We will have to start notifying customers in the coming month and two that they will need to start looking for alternative options ...

I rate Hims as a strong buy for a 3 to 6-month timeframe and plan to accumulate shares in the mid-$30s over the next few days. If the selloff doesn’t reach that level, I may enter in the low $40s.

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Additionally, the drug maker has decided to reduce the price of its 2.5 milligram dose to $349 per month. Hims sells semaglutide for $165 per month if patients pay for a 12-month supply of the ...